To leverage the potential of our unique technology, Imcyse is also entering private, public and academic partnerships. In March 2020, Imcyse became a proud member of INNODIA, a global network of academic institutions, industrial partners, patient organizations and a small-sized enterprise bringing together their knowledge and experience to fight type 1 diabetes (T1D), Imcyse’s lead indication. This private-public partnership offers Imcyse greater access to T1D patients as well as to a platform of scientific exchange and technical approaches that will help the Company as it further refines treatment with ImotopesTM for patients with early T1D.
